Editas CEO Cindy Collins leaves

  • Push-out Score determined
  • After less than two years in the position
  • Praise and thanks for Collins
  • Jim Mullen taking over
  • Collins said 63 words

(exechange) — Cambridge, Massachusetts, February 8, 2021 — Cindy Collins, chief executive of Editas, leaves. As announced by Editas Medicine Inc. in a news release and in a regulatory filing published on Monday, February 8, 2021, Cynthia (Cindy) Collins leaves her post as chief executive officer of the genome editing company after less than two years in the role, effective February 15, 2021.

Cindy Collins’s duties as CEO will be taken over by James C. (Jim) Mullen, currently Chairman of the Board of Directors of Editas Medicine Inc.

No reason given

In the announcement, Editas did not explicitly explain the reason for Cindy Collins’s move, leaving room for speculation.

Precise information regarding Cindy Collins’s future plans was not immediately available.

Editas said: “James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021.”

Share price increase since February 2020

The announcement follows an increase in Editas Medicine Inc.’s share price of 136% since February 2020.

In the position of CEO since 2019

Cindy Collins became CEO of the Company in 2019.

Cynthia Collins joined the Company’s Board in December 2018, has served as the Company’s President and Chief Executive Officer since August 2019 and previously served as the Company’s interim Chief Executive Officer from March 2019 until August 2019.

Collins previously served as the Chief Executive Officer of Human Longevity, Inc. (“Human Longevity”), a genomics company, from January 2017 to December 2017.

Prior to joining Human Longevity, Collins served as the Chief Executive Officer and GM of the Cell Therapy and Lab Businesses of GE Healthcare Life Sciences, a division of General Electric Company (“GE Healthcare”), a global digital industrial company, from April 2015 to December 2016, and as CEO of Clarient Diagnostics, Inc., a division of GE Healthcare, from October 2013 to April 2015.

Prior to GE Healthcare, she served as Chief Executive Officer and director of GenVec, Inc., a public biopharmaceutical company, from May 2012 to September 2013 and as Group Vice President, Cellular Analysis of Beckman Coulter, a global supplier of diagnostic solutions, from 2007 to 2011.

Collins also serves on the board of directors of Triumvira Immunologics, Inc., a private biotechnology company, since April 2018, DermTech, Inc., a public diagnostics company, since May 2018 and Biocare Medical, LLC, a private instrumentation and reagents company, since September 2018.

Collins also served on the board of directors of Provista Dx, a private diagnostics company, from March 2018 until December 2018 and Cavidi AB, a private research and clinical diagnostics company, from March 2018 until June 2019.

Collins received a BS, Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business.

Push-out Score determined

The Push-out Score™ determined by exechange gauges the pressure surrounding Cindy Collins’s move on a scale of 0 to 10.

exechange reached out to Editas and offered the company the opportunity to comment on the score.

Read the full story in the exechange report 7.2021 ($).